Denileukin diftitox: a concise clinical review

References

• Williams DP, Parker K, Bacha P et al. Diphtheria toxin receptor binding domain substitution with interleukin-2: genetic construction and properties of a diphtheria toxin-related interleukin-2 fusion protein. Protein Eng.1, 493–498 (1987).
   PubMedGoogle Scholar
• Bacha P, Williams DP, Waters C et al. Interleukin-2 receptor-targeted cytotoxicity. Interleukin-2 receptor-mediated action of a diphtheria toxin-related interleukin-2 fusion protein. J. Exp. Med.167, 612–622 (1988).
   PubMed Web of Science ®Google Scholar
• Kiyokawa T, Williams DP, Snider CE et al. Protein engineering of DAB-IL-2 fusion toxins to increase biologic potency. Ann. NY Acad. Sci.636, 331–339 (1991).
   PubMed Web of Science ®Google Scholar
• LeMaistre CF, Saleh MN, Kuzel TM et al. Phase I trial of a ligand fusion-protein (DAB389IL-2) in lymphomas expressing the receptor for interleukin-2. Blood91, 399–405 (1998).
   PubMed Web of Science ®Google Scholar
• Morris RE, Gerstein AS, Bonventre PF et al. Receptor-mediated entry of diphtheria toxin into monkey kidney (Vero) cells: electron microscopic evaluation. Infect. Immun.50, 721–727 (1985).
   PubMed Web of Science ®Google Scholar
• Moya M, Dautry-Varsat A, Goud B et al. Inhibition of coated pit formation in Hep2 cells blocks the cytotoxicity of diphtheria toxin but not that of ricin toxin. J. Cell Biol.101, 548–559 (1985).
   PubMed Web of Science ®Google Scholar
• Fuchs R, Schmid S, Mellman I. A possible role for Na+,K+-ATPase in regulating ATP-dependent endosome acidification. Proc. Natl Acad. Sci. USA86, 539–543 (1989).
   PubMed Web of Science ®Google Scholar
• Kuzel TM, Rosen ST, Gordon LI et al. Phase I trial of the diphtheria toxin/interleukin-2 fusion protein DAB486IL-2: efficacy in mycosis fungoides and other non-Hodgkin’s lymphomas. Leuk. Lymphoma11, 369–377 (1993).
   PubMed Web of Science ®Google Scholar
• LeMaistre CF, Craig FE, Meneghetti C et al. Phase I trial of a 90-minute infusion of the fusion toxin DAB486IL-2 in hematological cancers. Cancer Res.53, 3930–3934 (1993).
   PubMed Web of Science ®Google Scholar
• LeMaistre CF, Meneghetti C, Rosenblum M et al. Phase I trial of an interleukin-2 (IL-2) fusion toxin (DAB486IL-2) in hematologic malignancies expressing the IL-2 receptor. Blood.79, 2547–2554 (1992).
   PubMed Web of Science ®Google Scholar
• Hesketh P, Caguioa P, Koh H et al. Clinical activity of a cytotoxic fusion protein in the treatment of cutaneous T-cell lymphoma. J. Clin. Oncol.11, 1682–1690 (1993).
   PubMed Web of Science ®Google Scholar
• Olsen E, Duvic M, Frankel A et al. Pivotal Phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J. Clin. Oncol.19, 376–388 (2001).
   PubMed Web of Science ®Google Scholar
• Foss FM, Bacha P, Osann KE et al. Biological correlates of acute hypersensitivity events with DAB(389)IL-2 (denileukin diftitox, Ontak) in cutaneous T-cell lymphoma: decreased frequency and severity with steroid premedication. Clin. Lymphoma1, 298–302 (2001).
   PubMedGoogle Scholar
• Chin KM, Stark P, Foss FM. Outcomes in cutaneous T-cell lymphoma patients treated with denileukin diftitox. Proc. Am. Soc. Clin. Oncol.22, 591 (2003) (Abstract 2376).
   Google Scholar
• Shao R, Urbano A, Foss F. Modulation of DAB389IL-2 (Ontak) cytotoxicity in leukemia and lymphoma by arginine butyrate and all-trans retinoic acid. Proc. Am. Soc. Clin. Oncol. (2000) (Abstract 66).
   Google Scholar
• Dang NH, Hagemeister F, Fayad L et al. Interim analysis of a Phase II study of denileukin diftitox (Ontak) for B and T-cell non-Hodgkin’s lymphoma. Proc. Am. Soc. Clin. Oncol.22, 570 (2003) (Abstract 2292).
   Web of Science ®Google Scholar
• Dang NH, Hagemeister FB, Pro B et al. Phase II Study of denileukin diftitox for relapsed/refractory B-cell non-Hodgkin’s lymphoma. J. Clin. Oncol.22, 4095–4102 (2004).
   PubMed Web of Science ®Google Scholar
• Frankel AE, Fleming DR, Hall PD et al. A Phase II study of DT fusion protein denileukin diftitox in patients with fludarabine-refractory chronic lymphocytic leukemia. Clin. Cancer Res.9, 3555–3561 (2003).
   PubMed Web of Science ®Google Scholar
• Morgan SJ, Seymour JF, Prince HM, Westerman DA, Wolf MM. Confirmation of the activity of the interleukin-2 fusion toxin denileukin diftitox against chemorefractory chronic lymphocytic leukemia, including cases with chromosome 17p deletions and without detectable CD25 expression. Clin. Cancer Res.10, 3572–3575 (2004).
   PubMed Web of Science ®Google Scholar
• Gerena Lewis MA, R Shukla, Kleykamp B, Jazieh AR, Hainsworth J. A Phase II trial of denileukin diftitox – in previously treated, advanced non-small cell lung cancer (NSCLC). Proc. Am. Soc. Clin. Oncol. (2004) (Abstract 7292).
   Google Scholar
• Gottlieb AB, Bacha P, Parker K, Strand V. Use of interleukin-2 fusion protein, DAB389IL-2, for the treatment of psoriasis. Dermatol. Ther.5, 48–63 (1998).
   Google Scholar
• Bagel J, Garland WT, Breneman D et al. Administration of DAB389IL-2 to patients with recalcitrant psoriasis: a double-blind, Phase II multicenter trial. J. Am. Acad. Dermatol.38, 938–944 (1998).
   PubMed Web of Science ®Google Scholar
• Martin A, Gutierrez E, Muglia J et al. A multicenter dose-escalation trial with denileukin diftitox (Ontak, DAB(389)IL-2) in patients with severe psoriasis. J. Am. Acad. Dermatol.45, 871–881 (2001).
   PubMed Web of Science ®Google Scholar
• Ho VT, Zahrieh D, Hochberg E et al. Safety and efficacy of denileukin diftitox in patients with steroid-refractory acute graft versus host disease after allogeneic hematopoietic stem cell transplantation. Blood104, 1224–1226 (2004).
   PubMed Web of Science ®Google Scholar
• Vieweg J, Su Z, Dannull J. Enhancement of antitumor immunity following depletion of CD4+CD25+ regulatory T-cells. Proc. Am. Soc. Clin. Oncol. (2004) (Abstract 2506).
   Google Scholar
• Pichardo DA, Querfeld C, Guitart J et al. Cutaneous T-cell lymphoma: a paradigm for biological therapies. Leuk. Lymphoma45, 1755–1765 (2004).
   PubMed Web of Science ®Google Scholar